Jamil Asselah

2.1k total citations
29 papers, 373 citations indexed

About

Jamil Asselah is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jamil Asselah has authored 29 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Jamil Asselah's work include Esophageal Cancer Research and Treatment (6 papers), Esophageal and GI Pathology (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Jamil Asselah is often cited by papers focused on Esophageal Cancer Research and Treatment (6 papers), Esophageal and GI Pathology (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Jamil Asselah collaborates with scholars based in Canada, United States and Spain. Jamil Asselah's co-authors include Nathaniel Bouganim, Thierry Alcindor, George Zogopoulos, O. Donnay, Vilma Pacheco-Barcía, Catherine Sperlich, Laurent Azoulay, Jacobo Rogado, Lorenzo Ferri and T. France and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Jamil Asselah

27 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jamil Asselah Canada	11	224	120	116	88	64	29	373
Tetsuya Urasaki Japan	12	205 0.9×	107 0.9×	99 0.9×	50 0.6×	73 1.1×	53	416
Valentina Tateo Italy	10	205 0.9×	150 1.3×	106 0.9×	96 1.1×	114 1.8×	36	437
Dušica Gavrilović Serbia	13	185 0.8×	91 0.8×	70 0.6×	70 0.8×	72 1.1×	54	352
Ashish Manne United States	10	300 1.3×	100 0.8×	107 0.9×	41 0.5×	57 0.9×	44	430
Elisabetta Fenocchio Italy	12	242 1.1×	87 0.7×	73 0.6×	99 1.1×	53 0.8×	29	337
Laith Abushahin United States	10	409 1.8×	174 1.4×	127 1.1×	90 1.0×	45 0.7×	30	500
Hiroki Fukunaga Japan	10	241 1.1×	97 0.8×	140 1.2×	83 0.9×	173 2.7×	23	474
Takefumi Yoshida Japan	11	212 0.9×	58 0.5×	124 1.1×	97 1.1×	98 1.5×	38	394
Lars H. Jørgensen Norway	14	124 0.6×	129 1.1×	174 1.5×	162 1.8×	177 2.8×	30	565
Aurélie Ferru France	11	250 1.1×	82 0.7×	39 0.3×	86 1.0×	93 1.5×	30	439

Countries citing papers authored by Jamil Asselah

Since Specialization

Citations

This map shows the geographic impact of Jamil Asselah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamil Asselah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamil Asselah more than expected).

Fields of papers citing papers by Jamil Asselah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamil Asselah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamil Asselah. The network helps show where Jamil Asselah may publish in the future.

Co-authorship network of co-authors of Jamil Asselah

This figure shows the co-authorship network connecting the top 25 collaborators of Jamil Asselah. A scholar is included among the top collaborators of Jamil Asselah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamil Asselah. Jamil Asselah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McArthur, Heather L., Sara M. Tolaney, Rebecca Dent, et al.. (2025). TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer. Therapeutic Advances in Medical Oncology. 17. 22760912–22760912. 9 indexed citations

Loibl, Sibylle, Barbara Pistilli, Rebecca Dent, et al.. (2024). 159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC). ESMO Open. 9. 103146–103146. 1 indexed citations

Tankel, James, Jonathan Spicer, Sara Najmeh, et al.. (2024). Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score–matched analysis. Journal of Gastrointestinal Surgery. 28(6). 916–922. 2 indexed citations

Ramjeesingh, Ravi, Prosanto Chaudhury, Vincent C. Tam, et al.. (2023). A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada. Current Oncology. 30(8). 7132–7150. 8 indexed citations

Henning, Jan‐Willem, Christine Brezden‐Masley, Karen A. Gelmon, et al.. (2023). Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective. Current Oncology. 30(9). 8019–8038. 17 indexed citations

Schmid, Peter, Piotr J. Wysocki, X. Cynthia, et al.. (2023). 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. Annals of Oncology. 34. S337–S337. 25 indexed citations

Tankel, James, Carmen Mueller, Jonathan Spicer, et al.. (2023). Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network. Annals of Surgical Oncology. 31(4). 2461–2469.

France, T., Jamil Asselah, R. Mondéjar, et al.. (2020). 153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer. Annals of Oncology. 31. S300–S300. 1 indexed citations

Pacheco-Barcía, Vilma, T. France, Jamil Asselah, et al.. (2019). A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 20(2). 254–264. 57 indexed citations

10.

Pacheco-Barcía, Vilma, T. France, George Zogopoulos, et al.. (2018). Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival. Annals of Oncology. 29. v46–v46. 7 indexed citations

11.

Finn, Richard S., Karen A. Gelmon, Johannes Ettl, et al.. (2017). Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis. Annals of Oncology. 28. v79–v80. 2 indexed citations

12.

Savage, Paul, Alexis Blanchet-Cohen, Timothée Revil, et al.. (2017). A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Reports. 21(5). 1140–1149. 61 indexed citations

13.

Dabbs, David J., Charles E. Cox, Steven C. Shivers, et al.. (2017). Multi-institutional comparison of breast cancer risk stratification by 70-gene signature and 21-gene assay.. Journal of Clinical Oncology. 35(15_suppl). 522–522. 1 indexed citations

14.

Hammel, Pascal, Jill Lacy, Fabienne Portales, et al.. (2016). P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC). Annals of Oncology. 27. ii78–ii78. 1 indexed citations

15.

Bouganim, Nathaniel, et al.. (2016). The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer. British Journal of Cancer. 116(1). 103–108. 21 indexed citations

16.

Simoneau, Ève, Murad Aljiffry, Louis-Martin Boucher, et al.. (2016). Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. Journal of Surgical Oncology. 113(4). 449–455. 27 indexed citations

17.

Sudarshan, Monisha, Thierry Alcindor, Steven Ades, et al.. (2014). Survival and Recurrence Patterns after Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophagogastric Adenocarcinoma. Annals of Surgical Oncology. 22(1). 324–330. 16 indexed citations

18.

Cools‐Lartigue, Jonathan, D. G. Jones, Jonathan Spicer, et al.. (2014). Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?. Annals of Surgical Oncology. 22(6). 1858–1865. 22 indexed citations

19.

Asselah, Jamil & Catherine Sperlich. (2013). Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Canadian Urological Association Journal. 7(2). S11–7. 10 indexed citations

20.

Saad, Fred & Jamil Asselah. (2013). Chemotherapy for prostate cancer: Clinical practice in Canada. Canadian Urological Association Journal. 7(2). S5–S10. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact